Evidence map›Paper›PMID 39858894›Full record

ArticleMicroorganisms2025

Reduced Presence of SARS-CoV-2 microRNA-like Small RNA in the Serum of Patients with Post-Acute Sequelae SARS-CoV-2 Infection.

Maria Alfreda Stincarelli, Isabella Abbate, Giulia Matusali, Michele Tanturli, Marta Camici, Rosaria Arvia, Elisabetta Lazzari, Eleonora Cimini, Alessandra Vergori, Fabrizio Maggi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Alfreda StincarelliDepartment of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 48, 50134 Florence, Italy.ORCID 0000-0003-1046-4565
Isabella AbbateLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
Giulia MatusaliLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0000-0002-2948-4243
Michele TanturliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50121 Florence, Italy.ORCID 0000-0002-2642-1706
Marta CamiciClinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0000-0002-6624-7917
Rosaria ArviaDepartment of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 48, 50134 Florence, Italy.
Elisabetta LazzariLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0009-0008-0558-0610
Eleonora CiminiCellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0000-0002-2659-0868
Alessandra VergoriClinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0000-0001-6944-0686
Fabrizio MaggiLaboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.ORCID 0000-0001-7489-5271
Simone GiannecchiniDepartment of Experimental and Clinical Medicine, University of Florence, Viale Morgagni 48, 50134 Florence, Italy.ORCID 0000-0003-3374-7621

Funding

Istituto di Ricerca Virologica Oretta Bartolomei Corsi'' Florence, Italy 2021National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149, Rome (It-aly Programma Ricerca Corrente-Linea 1 on emerging and re-emerging infections
6 · The paper itself

Abstract

The mechanisms underlying post-acute sequelae of SARS-CoV-2 infection (PASC) are a topic of debate. This study examined the presence of SARS-CoV-2 microRNA (miRNA)-like small RNAs in extracellular fluids and their potential link to PASC by using a quantitative stem-loop RT-PCR MiRNA assay. Initially, it was demonstrated that three previously identified SARS-CoV-2 miRNA-like small RNAs, specifically svRNA 1 and 2 and miR-07a, were significantly expressed in infected cells in vitro and released into the supernatant following infection by different SARS-CoV-2 variants. Then, the expression of three SARS-CoV-2 small RNAs was studied in both nasopharyngeal swabs (NPS) and sera from 24 patients at their initial COVID-19 diagnosis (T0) and in sera collected 91 to 193 days post-diagnosis (T1). Notably, 11 out of 24 patients (46%) reported PASC consequences. All NPS samples showed SARS-CoV-2 small RNA expression with an altered cytokine network during acute infection, but it did not correlate with PASC outcomes. Serum samples had similar small RNA statuses, though PASC patients, notably at T1, but not at T0, displayed reduced overall positivity compared to those without PASC. The host target expression of SARS-CoV-2 small RNAs was not significantly different between groups. This suggests a need for further research into SARS-CoV-2 small RNA and its role in viral behavior and PASC consequences.

Indexed as

extracellular vesiclesmicroRNAPASCSARS-CoV-2small RNA

Identifiers

PMID39858894
PMCPMC11767842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.